Evdoxia Kyriazopoulou

Evdoxia, MD, MSc, Ph.D. was born and studied Medicine in Athens, Greece. She was trained in Internal Medicine in Heilbronn, Germany (2011-2013) and finished her clinical training in the 4th Department of Internal Medicine, University of Athens (2014-2016). She received a Ph.D. in biomarker-guided treatment in sepsis from the same University in 2020. Her main research interests are the immunology of sepsis, sepsis biomarkers, immunomodulation in sepsis, and COVID-19. She was awarded the first prize “Sotirios Papastamatis” in 2016 for her research on Macrophage Activation-like Syndrome in sepsis and was the main investigator of the SAVE and SAVE-MORE clinical trials, the results of which led to the authorization approval of anakinra for COVID-19 by the European Medicines Agency. Currently, she works as an Intensivist in the 2nd Department of Critical Care Medicine, at the University of Athens and her postdoctoral research focuses on the role of immune dysregulation in post- and long- Covid syndrome. She is a member of the Hellenic Sepsis Study Group, the European Shock Society, the European Society of Clinical Microbiology and Infectious Diseases, and the International Society of Antimicrobial Chemotherapy Early Career Working Group.